| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
1 Laboratoire de génomique fonctionnelle de l'Université de Sherbrooke, 2 Département de pathologie, and 3 Département de microbiologie et d'infectiologie, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, Québec, Canada
Requests for reprints: Sherif Abou Elela, Département de microbiologie et d'infectiologie, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke, Québec, Canada J1H 5N4. Phone: 819-564-5275; E-mail: sherif.abou.elela{at}usherbrooke.ca.
Key Words: alternative splicing • ovarian cancer • RT-PCR • genomics • Rnomics
Intense efforts are currently being directed toward profiling gene expression in the hope of developing better cancer markers and identifying potential drug targets. Here, we present a sensitive new approach for the identification of cancer signatures based on direct high-throughput reverse transcription-PCR validation of alternative splicing events. This layered and integrated system for splicing annotation (LISA) fills a gap between high-throughput microarray studies and high-sensitivity individual gene investigations, and was created to monitor the splicing of 600 cancer-associated genes in 25 normal and 21 serous ovarian cancer tissues. Out of >4,700 alternative splicing events screened, the LISA identified 48 events that were significantly associated with serous ovarian tumor tissues. In a further screen directed at 39 ovarian tissues containing cancer pathologies of various origins, our ovarian cancer splicing signature successfully distinguished all normal tissues from cancer. High-volume identification of cancer-associated splice forms by the LISA paves the way for the use of alternative splicing profiling to diagnose subtypes of cancer. [Cancer Res 2008;68(3):657–63]
This article has been cited by other articles:
|
|
 |
|
  J. P. Venables, R. Klinck, A. Bramard, L. Inkel, G. Dufresne-Martin, C. Koh, J. Gervais-Bird, E. Lapointe, U. Froehlich, M. Durand, et al. Identification of Alternative Splicing Markers for Breast Cancer Cancer Res., November 15, 2008; 68(22): 9525 - 9531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Venables, C.-S. Koh, U. Froehlich, E. Lapointe, S. Couture, L. Inkel, A. Bramard, E. R. Paquet, V. Watier, M. Durand, et al. Multiple and Specific mRNA Processing Targets for the Major Human hnRNP Proteins Mol. Cell. Biol., October 1, 2008; 28(19): 6033 - 6043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rival, E. Jaligot, T. Beule, and E. J. Finnegan Isolation and expression analysis of genes encoding MET, CMT, and DRM methyltransferases in oil palm (Elaeis guineensis Jacq.) in relation to the 'mantled' somaclonal variation J. Exp. Bot., September 1, 2008; 59(12): 3271 - 3281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Fackenthal and L. A. Godley Aberrant RNA splicing and its functional consequences in cancer cells Dis. Model. Mech., July 1, 2008; 1(1): 37 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hai, W. Cao, G. Liu, S.-P. Hong, S. A. Elela, R. Klinck, J. Chu, and J. Xie A G-tract element in apoptotic agents-induced alternative splicing Nucleic Acids Res., June 1, 2008; 36(10): 3320 - 3331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Shkreta, U. Froehlich, E. R. Paquet, J. Toutant, S. A. Elela, and B. Chabot Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes Mol. Cancer Ther., June 1, 2008; 7(6): 1398 - 1409. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
